logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11674182 B1

PDFFull Text
Date of Patent:
Jun. 13, 2023

Filed:

Mar. 08, 2018

Biomarker for her2-positive cancer and anti-her2 therapy and applications thereof

Applicant:

Industry-university Cooperation Foundation Hanyang University, Seoul, KR;

Inventors:

Gu Kong, Seoul, KR;

Jeong-Yeon Lee, Seoul, KR;

Hyeong-Seok Joo, Seoul, KR;

Assignee:

INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY, Seoul, KR;

Attorney:

Sughrue Mion, PLLC

Primary Examiner:

Sean E Aeder

Int. Cl.
CPC ...
C12Q 1/6886 (2018.01); A61K 39/00 (2006.01); A61K 31/18 (2006.01); A61K 31/216 (2006.01); A61K 31/426 (2006.01); A61K 31/438 (2006.01); A61K 31/4406 (2006.01); A61K 31/444 (2006.01); A61K 31/496 (2006.01); C07K 16/32 (2006.01); G01N 33/574 (2006.01);
U.S. Cl.
CPC ...
C12Q 1/6886 (2013.01); A61K 31/18 (2013.01); A61K 31/216 (2013.01); A61K 31/426 (2013.01); A61K 31/438 (2013.01); A61K 31/444 (2013.01); A61K 31/4406 (2013.01); A61K 31/496 (2013.01); A61K 39/001106 (2018.08); C07K 16/32 (2013.01); G01N 33/5748 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01);
Abstract

The present invention provides MEL-18, which is a biomarker for human epidermal growth factor receptor2 (HER2)-positive cancer and anti-HER2 therapy, and a use thereof. According to the present invention, MEL-18 is a prognostic factor or predictor for a response of subjects to an anti-HER2-targeted drug in HER2-POSITIVE cancer and may be used in companion diagnostics for HER2-targeted drugs in subjects with HER2-positive cancer. Therefore, HER2-positive cancer may be more effectively treated by overcoming resistance to HER2 therapeutic agents and enhancing therapeutic efficacy by determining whether ADAM10/17 inhibitors are administered or co-administered with HER2-targeted drugs.

Find Patent Forward Citations

Loading…